➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Baxter
Colorcon
McKesson
McKinsey

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

RIZATRIPTAN BENZOATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Rizatriptan Benzoate patents expire, and what generic alternatives are available?

Rizatriptan Benzoate is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Mylan Pharms Inc, Natco Pharma Ltd, Panacea Biotec Ltd, Sandoz, Unichem Labs Ltd, Alkem Labs Ltd, Celltrion, Eci Pharms Llc, Emcure Pharms Ltd, Glenmark Generics, Invagen Pharms, and Teva Pharms. and is included in twenty-five NDAs.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

US ANDA Litigation and Generic Entry Outlook for Rizatriptan Benzoate

A generic version of RIZATRIPTAN BENZOATE was approved as rizatriptan benzoate by AUROBINDO PHARMA LTD on December 31st, 2012.

  Start Trial

Drug patent expirations by year for RIZATRIPTAN BENZOATE
Drug Prices for RIZATRIPTAN BENZOATE

See drug prices for RIZATRIPTAN BENZOATE

Drug Sales Revenue Trends for RIZATRIPTAN BENZOATE

See drug sales revenues for RIZATRIPTAN BENZOATE

Recent Clinical Trials for RIZATRIPTAN BENZOATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 3

See all RIZATRIPTAN BENZOATE clinical trials

Paragraph IV (Patent) Challenges for RIZATRIPTAN BENZOATE
Tradename Dosage Ingredient NDA Submissiondate
MAXALT-MLT TABLET, ORALLY DISINTEGRATING;ORAL rizatriptan benzoate 020865 2006-02-17
MAXALT TABLET;ORAL rizatriptan benzoate 020864 2004-09-02

US Patents and Regulatory Information for RIZATRIPTAN BENZOATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 201993-001 Dec 31, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Emcure Pharms Ltd RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 204090-002 Nov 26, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Unichem Labs Ltd RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 207836-001 Mar 7, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sandoz RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET;ORAL 079230-001 Dec 31, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Merck
Boehringer Ingelheim
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.